在临床前阶段诊断阿尔茨海默氏病:正常衰老或痴呆症
IEEE reviews in biomedical engineering
|March 13, 2024
概括
这篇评论探讨了阿尔茨海默病 (AD) 在生物流体和行为中的特征. 它讨论了通过治疗点检测 (POCT) 设备早期检测AD的生物传感机制.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 生物化学 生物化学
背景情况:
- 阿尔茨海默氏病 (AD) 带来了诊断挑战,尤其是在早期,影响了患者,并产生了重大的全球成本.
- 目前阿尔茨海默病的诊断方法往往是侵入性的,昂贵的,劳动密集的,限制了生物标志物研究和临床检测 (POCT) 的发展.
- 现有的AD生物传感技术缺乏效率,可重复性和准确的标记物识别,阻碍了商业化.
研究的目的:
- 审查在生物流体和身体行为中发现有前途的阿尔茨海默病 (AD) 标志.
- 讨论各种生物传感机制及其在诊断AD方面的挑战.
- 突出新型生物传感器在POCT环境中早期发现AD的潜力.
主要方法:
- 目前阿尔茨海默病 (AD) 生物标志物的文献综述.
- 分析各种生物传感机制及其局限性.
- 探索用于AD诊断的生物传感器技术的最新进展.
主要成果:
- 在生物流体和行为指标中识别多样化和有前途的AD标志.
- 讨论与当前生物感知方法相关的挑战.
- 突出新生物传感器的潜力,以改善早期AD检测.
结论:
- 开发高效准确的生物传感器对于克服当前AD诊断局限性至关重要.
- 新型生物传感技术对通过临床检测 (POCT) 早期发现阿尔茨海默病 (AD) 具有重大前景.
- 未来的研究应该专注于创建紧的,多用途的设备,以便便于及时诊断AD.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Cognitive Development During Adulthood
98
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
98
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


